PE20060626A1 - Aminas policiclicas sustituidas con arilo como antagonistas de mch1r - Google Patents

Aminas policiclicas sustituidas con arilo como antagonistas de mch1r

Info

Publication number
PE20060626A1
PE20060626A1 PE2005000948A PE2005000948A PE20060626A1 PE 20060626 A1 PE20060626 A1 PE 20060626A1 PE 2005000948 A PE2005000948 A PE 2005000948A PE 2005000948 A PE2005000948 A PE 2005000948A PE 20060626 A1 PE20060626 A1 PE 20060626A1
Authority
PE
Peru
Prior art keywords
alkyl
polycyclical
aryl
mch1r
antagonists
Prior art date
Application number
PE2005000948A
Other languages
English (en)
Inventor
Matthias Gossel
Siegfried Stengelin
Lothar Schwink
Gerhard Hessler
Petra Stahl
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PE20060626A1 publication Critical patent/PE20060626A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Abstract

REFERIDA A UN COMPUESTO AMINA POLICICLICA SUSTITUIDA CON ARILO DE FORMULA I, DONDE A, B, D Y G SON N, C(R3), ENTRE OTROS; R3 ES H, F, OH, CN, ENTRE OTROS; R4, R5, R6, R7, R8 Y R10 SON H, ALQUILO C1-C8, ENTRE OTROS; x ES 0, 1, 2, 3, 4, 5 O 6; R1 ES H, ALQUILO C1-C8, ALQUENILO C3-C6, ENTRE OTROS; X ES N(R16), O, UN ENLACE, ENTRE OTROS; Y ES O, S, C=O, N(R21); K ES UN ENLACE, (CR33R34)z, ENTRE OTROS; z ES 1, 2, 3, 4, 5 O 6; R2 ES H, ALQUILO C1-C8, ENTRE OTROS; E ES UN ANILLO CARBOCICLICA O HETEROCICLICA BIVALENTE DE 3 A 14 MIEMBROS CON 0 A 4 HETEROATOMOS DEL GRUPO N, O Y S, QUE PUEDE LLEVAR OPCIONALMENTE SUSTITUYENTES H, F, Br, ENTRE OTROS; Q ES UN ANILLO BI-, TRI- O ESPIROCICLICA SATURADA O PARCIALMENTE INSATURADA CON UN ATOMO DE NITROGENO Y OTROS 0 A 3 HETEROATOMOS SELECCIONADOS DE N, O Y S, ENTRE OTROS; R33 Y R34 SON H, ALQUILO C1-C8, OH, ENTRE OTROS. DICHO COMPUESTO ES ANTAGONISTA DEL RECEPTOR MCH1R Y ES UTIL PARA EL TRATAMIENTO DE LA OBESIDAD Y DIABETES
PE2005000948A 2004-08-16 2005-08-15 Aminas policiclicas sustituidas con arilo como antagonistas de mch1r PE20060626A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004039789A DE102004039789A1 (de) 2004-08-16 2004-08-16 Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
PE20060626A1 true PE20060626A1 (es) 2006-08-08

Family

ID=35610053

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2005000948A PE20060626A1 (es) 2004-08-16 2005-08-15 Aminas policiclicas sustituidas con arilo como antagonistas de mch1r
PE2005000947A PE20060497A1 (es) 2004-08-16 2005-08-15 Aminas policiclicas sustituidas con arilo como antagonistas de mch

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2005000947A PE20060497A1 (es) 2004-08-16 2005-08-15 Aminas policiclicas sustituidas con arilo como antagonistas de mch

Country Status (28)

Country Link
US (5) US7838547B2 (es)
EP (2) EP1781656B1 (es)
JP (2) JP2008509958A (es)
KR (2) KR20070053225A (es)
CN (2) CN101006091B (es)
AR (2) AR050604A1 (es)
AT (1) ATE381564T1 (es)
AU (2) AU2005274314A1 (es)
BR (2) BRPI0514365A (es)
CA (2) CA2577261A1 (es)
CY (1) CY1108077T1 (es)
DE (2) DE102004039789A1 (es)
DK (1) DK1781656T3 (es)
ES (1) ES2297758T3 (es)
IL (2) IL181008A0 (es)
MA (1) MA28795B1 (es)
MX (2) MX2007001584A (es)
MY (1) MY145133A (es)
NO (1) NO20071271L (es)
PE (2) PE20060626A1 (es)
PL (1) PL1781656T3 (es)
PT (1) PT1781656E (es)
RU (1) RU2007109600A (es)
SI (1) SI1781656T1 (es)
TW (2) TW200621780A (es)
UY (2) UY29071A1 (es)
WO (2) WO2006018279A2 (es)
ZA (1) ZA200700354B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004039789A1 (de) * 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101065356A (zh) * 2004-10-01 2007-10-31 万有制药株式会社 2－芳基甲酰胺－含氮杂环化合物
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7728031B2 (en) * 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
MX2008013400A (es) * 2006-04-19 2008-11-10 Astellas Pharma Inc Derivado de azolcarboxamida.
DE102006021874B4 (de) 2006-05-11 2008-03-27 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
EA015488B1 (ru) 2006-10-18 2011-08-30 Пфайзер Продактс Инк. Содержащие диариловый эфир соединения мочевины
AU2007328979B2 (en) * 2006-12-05 2013-05-09 Janssen Pharmaceutica N.V. Novel substituted diaza spiro pyridinone derivatives for use in MCH-1 mediated diseases
US8383852B2 (en) * 2007-02-16 2013-02-26 Emisphere Technologies, Inc. Compounds having a cyclic moiety and compositions for delivering active agents
WO2008109285A1 (en) 2007-03-06 2008-09-12 Allergan, Inc. Methods for treating cognitive disorders
CA2685266C (en) 2007-04-27 2014-01-28 Purdue Pharma L.P. Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal
TW200916472A (en) * 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
RU2486187C2 (ru) 2007-09-11 2013-06-27 Эбботт Лэборетриз N-ОКСИДЫ ОКТАГИДРО-ПИРРОЛО[3,4-b]ПИРРОЛА
MX2010004499A (es) 2007-10-24 2010-05-20 Astellas Pharma Inc Compuesto de azolcarboxamida o sal de el.
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP2321364B1 (en) * 2008-08-22 2015-08-12 Novomer, Inc. Methods for polymer synthesis
AU2009316795A1 (en) * 2008-11-19 2010-05-27 Schering Corporation Inhibitors of diacylglycerol acyltransferase
PE20110833A1 (es) * 2008-11-26 2011-12-21 Abbott Lab Nuevas octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueantes de los canales de calcio
US8691865B2 (en) 2008-11-26 2014-04-08 Abbvie Inc. Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
PE20120057A1 (es) 2008-12-19 2012-02-24 Sirtris Pharmaceuticals Inc Compuestos de tiazolopiridina moduladores de sirtuina
BR112012003973A2 (pt) 2009-08-26 2015-09-08 Sanofi Sa hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8796470B2 (en) 2010-05-25 2014-08-05 Abbvie Inc. Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators
AU2011265047B2 (en) 2010-06-07 2014-10-23 Novomedix, Llc Furanyl compounds and the use thereof
WO2012071369A2 (en) 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2723732B1 (en) 2011-06-22 2017-01-18 Purdue Pharma LP Trpv1 antagonists including dihydroxy substituent and uses thereof
SI3057964T1 (sl) 2013-10-14 2020-03-31 Eisai R&D Management Co., Ltd. Selektivno substituirane spojine kinolina
CN105636945B (zh) 2013-10-14 2017-11-17 卫材R&D管理有限公司 选择性取代的喹啉化合物
JP2017525753A (ja) 2014-06-06 2017-09-07 フレクサス・バイオサイエンシーズ・インコーポレイテッドＦｌｅｘｕｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 免疫調節剤
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
CN107205970A (zh) 2014-11-05 2017-09-26 弗莱塞斯生物科学公司 免疫调节剂
AR102537A1 (es) * 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
MA43706B1 (fr) 2016-03-17 2020-09-30 Hoffmann La Roche Dérivé de 5-éthyl-4-méthyl-pyrazole-3-carboxamide ayant une activité en tant qu'agoniste de taar
DK3483164T3 (da) 2017-03-20 2020-03-23 Forma Therapeutics Inc Pyrrolopyrrolsammensætninger som pyruvatkinase (pkr) aktivatorer
US11299481B2 (en) 2017-10-20 2022-04-12 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
CN111565718A (zh) 2017-10-31 2020-08-21 范德比尔特大学 毒蕈碱性乙酰胆碱受体m4的拮抗剂
KR20200116945A (ko) 2018-02-02 2020-10-13 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 길항제
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
CN113845427A (zh) * 2021-09-07 2021-12-28 华东师范大学 芳基醇、芳基酮、芳基羧酸化合物及其合成方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9314973D0 (en) 1993-07-20 1993-09-01 Smithkline Beecham Plc Medicaments
DE50008597D1 (de) 1999-03-08 2004-12-16 Bayer Healthcare Ag Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel
WO2001021577A2 (en) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
DK2014285T3 (da) * 1999-11-26 2010-06-28 Shionogi & Co NPYY5-antagonister
DK1257550T3 (da) * 2000-02-04 2006-03-27 Portola Pharm Inc Blodplade-ADP-receptor-inhibitor
WO2002006245A1 (en) 2000-07-05 2002-01-24 Synaptic Pharmarceutical Corporation Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof
EP1246847A2 (en) 2000-07-05 2002-10-09 Synaptic Pharmaceutical Corporation Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
PL365183A1 (en) * 2000-07-31 2004-12-27 Smithkline Beecham P.L.C. Carboxamide compounds and their use as antagonists of a human 11cby receptor
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
JP2005507367A (ja) * 2001-04-13 2005-03-17 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド １，４−二置換ベンゾ縮合化合物
CA2446351A1 (en) 2001-05-04 2002-11-14 Tularik Inc. Fused heterocyclic compounds
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
RU2004115737A (ru) 2001-10-25 2005-10-10 Такеда Кемикал Индастриз, Лтд. (JP) Соединение хинолина
EP1450801A4 (en) * 2001-11-27 2010-10-27 Merck Sharp & Dohme 2-AMINOQUINOLINE COMPOUNDS
WO2003087044A2 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
WO2003097047A1 (en) 2002-05-13 2003-11-27 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TW200510311A (en) * 2002-12-23 2005-03-16 Millennium Pharm Inc CCr8 inhibitors
GB0320244D0 (en) * 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
NZ544244A (en) * 2003-07-03 2008-10-31 Hoffmann La Roche Dual NK1/NK3 antagonists for treating schizophrenia
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
DE102004039789A1 (de) * 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
DE502005002316D1 (de) 2008-01-31
CN101006091A (zh) 2007-07-25
CN101006091B (zh) 2010-09-15
JP2008509958A (ja) 2008-04-03
RU2007109600A (ru) 2008-09-27
AU2005274315A1 (en) 2006-02-23
TW200621781A (en) 2006-07-01
CN101006089A (zh) 2007-07-25
ZA200700354B (en) 2008-06-25
IL181008A0 (en) 2007-07-04
US8586609B2 (en) 2013-11-19
KR20070053225A (ko) 2007-05-23
US8357686B2 (en) 2013-01-22
TW200621780A (en) 2006-07-01
DK1781656T3 (da) 2008-05-05
EP1781656B1 (de) 2007-12-19
ATE381564T1 (de) 2008-01-15
PL1781656T3 (pl) 2008-03-31
IL181007A0 (en) 2007-07-04
BRPI0514365A (pt) 2008-06-10
PT1781656E (pt) 2008-02-01
WO2006018280A3 (de) 2006-05-11
US20070197584A1 (en) 2007-08-23
KR20070046868A (ko) 2007-05-03
PE20060497A1 (es) 2006-07-17
SI1781656T1 (sl) 2008-04-30
US20100298378A1 (en) 2010-11-25
US7569583B2 (en) 2009-08-04
MX2007001478A (es) 2007-04-19
US8163741B2 (en) 2012-04-24
US7838547B2 (en) 2010-11-23
US20090258881A1 (en) 2009-10-15
BRPI0514404A (pt) 2008-06-10
AR050604A1 (es) 2006-11-08
EP1781656A2 (de) 2007-05-09
EP1781663B1 (de) 2013-11-20
WO2006018279A2 (de) 2006-02-23
CY1108077T1 (el) 2014-02-12
ES2297758T3 (es) 2008-05-01
UY29071A1 (es) 2006-03-31
MA28795B1 (fr) 2007-08-01
CA2577255A1 (en) 2006-02-23
WO2006018279A3 (de) 2006-05-11
JP2008509957A (ja) 2008-04-03
AR050603A1 (es) 2006-11-08
WO2006018280A2 (de) 2006-02-23
AU2005274314A1 (en) 2006-02-23
MY145133A (en) 2011-12-30
NO20071271L (no) 2007-03-16
EP1781663A2 (de) 2007-05-09
UY29072A1 (es) 2006-03-31
DE102004039789A1 (de) 2006-03-02
MX2007001584A (es) 2007-04-20
CA2577261A1 (en) 2006-02-23
US20070299077A1 (en) 2007-12-27
US20090258872A1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
PE20060626A1 (es) Aminas policiclicas sustituidas con arilo como antagonistas de mch1r
AR061644A1 (es) Derivados de benzofurano
PE20130647A1 (es) Indoles
PE20120229A1 (es) Compuestos heterociclicos como inhibidores de proteasa aspartica
PE20091490A1 (es) Derivados sustituidos de indol
PE20030039A1 (es) Derivados de indol con afinidad por el receptor 5-ht6
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20071245A1 (es) COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs)
AR066606A1 (es) Compuestos de heteroarilamida pirimidona
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
AR049784A1 (es) Derivados sustituidos de morfolina y tiomorfolina
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
PE20020195A1 (es) AGONISTAS ß3 ADRENERGICOS
AR055878A1 (es) Derivados de ciclopropanocarboxamida
PE20050767A1 (es) Amino-benzazoles como inhibidores del receptor p2y1
PE20091093A1 (es) Compuesto heterociclico que contiene nitrogeno y su uso
ES2531396T3 (es) Proceso para preparar compuestos de piridinona
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
PE20160217A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales
CY1109015T1 (el) Διφαινυλ ενωσεις χρησιμες ως ανταγωνιστες μουσκαρινικου υποδοχεα
AR066421A1 (es) Compuestos derivados de piridona
PE20121159A1 (es) DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR
AR061486A1 (es) Derivados de 2-pirazinacarboxamida

Legal Events

Date Code Title Description
FC Refusal